Limbal stem cell deficiency (LSCD) is a painful eye disease that prevents the cornea renewing itself and can result in reduced vision or blindness, ocular irritation and visual glare. Current treatments for LSCD include standard corneal transplantation as well as limbal tissue grafting. However, both treatments have severe limitations in terms of success rates, the risk of tissue rejection and shortage of tissue supply, and can lead to the damage of donors’ healthy eyes.
The aim of this trial is to apply ex vivo limbal stem cells to address limbal stem cell deficiency (LSCD) to see if they can halt or repair damage to the eye.
Prof. Bal Dhillon, Eye Pavilion and Royal Infirmary, Edinburgh